Completed recruitment in their phase 3 heart failure trial. Is the company better today than yesterday - no... but is much closer to a potentially massive catalyst.
heart failure isnt like gvhd where msb is likely to gain fda approval... as a condition, it is very very common and thus the potential opportunity is huge - but this comes with a big if... the primary endpoint is met
this is a gamble, but as i see it, the trial is either positive in which case msb may well be worth a magnitude of times more than it currently is... or it fails and the indication isnt successful in which case the share price would drop and still represent a reasonable buying opportunity given the gvhd indication looks likely and theres several other trials underway
lots of ways to win very very big, minimal losses (in the longterm) except for wasted cash funding trials